PHS
GILD icon

PFM Health Sciences’s Gilead Sciences GILD Stock Holding History

PFM Health Sciences’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,412,500
Closed -$84M – 82
2022
Q1 		$84M Buy
+1,412,500
New +$90.3M 3.14% 8
2021
Q4 		– Sell
-963,700
Closed -$67.3M – 81
2021
Q3 		$67.3M Buy
+963,700
New +$67.7M 1.98% 16
2020
Q4 		– Sell
-350,000
Closed -$22.1M – 90
2020
Q3 		$22.1M Buy
+350,000
New +$24.3M 1.02% 38
2020
Q1 		– Sell
-3,024,200
Closed -$197M – 69
2019
Q4 		$197M Buy
+3,024,200
New +$197M 9.36% 1
2015
Q2 		– Sell
-740,800
Closed -$670K – 98
2015
Q1 		$670K Buy
+740,800
New +$75.2M 0.02% 82

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PFM Health Sciences's GILD Position: Q1 2026 in Review

PFM Health Sciences sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 71,018 shares — an estimated $8.72M sold.

PFM Health Sciences first reported a position in GILD in Q2 2013 and held it in 24 quarters. The position peaked at $357M in Q2 2013. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • PFM Health Sciences reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • PFM Health Sciences sold 71,018 Gilead Sciences shares in Q1 2026, an estimated $8.72M.
  • PFM Health Sciences first reported a position in Gilead Sciences in Q2 2013 and held it in 24 quarters.
  • PFM Health Sciences's Gilead Sciences position peaked at $357M in Q2 2013.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.